We prospectively followed up 589 patients to evaluate the relationship of anti-cytomegalovirus (CMV) treatment and immune reconstitution in response to highly active antiretroviral therapy (HAART) on the mortality risk of patients with CMV retinitis and acquired immune deficiency syndrome. The use of HAART was associated with an 81% lower mortality rate (95% confidence interval [CI], 74%-86%); it was 96% lower (95% CI, 92%-98%) for those who developed immune recovery and 49% lower (95% CI, 30-63%) for those who did not. Using time-updated multivariate analysis, current systemic anti-CMV treatment was independently associated with a 28% lower mortality rate (95% CI, 8%-43%). On the basis of these results, for patients who continue to have profound immunodeficiency despite HAART, the continued use of HAART and systemic anti-CMV therapy is predicted to reduce the risk of mortality by 65%, over and above the benefits of Pneumocystis carinii and Mycobacterium avium prophylaxis.
of patients with CMV retinitis treated with HAART is reduced [22] [23] [24] [25] [26] , but they did not evaluate whether such benefit occurs solely among those who develop immune recovery or more broadly. Also, the effects of systemic anti-CMV treatment on mortality risk are unclear: 2 HAART-era studies have reported opposite results [23, 26] . To clarify these issues, we report on the independent effects of systemic anti-CMV treatment and of HAART-accounting for the occurrence or absence of immune recovery-on survival in a large inception cohort of patients with CMV retinitis and AIDS.
PATIENTS AND METHODS

Population.
The Johns Hopkins CMV Retinitis Cohort consists of patients with AIDS and CMV retinitis who have been consecutively enrolled since the first case in October 1983; it has been estimated to include у80% of CMV retinitis cases among patients with AIDS in Baltimore [27, 28] . CMV retinitis was diagnosed by ophthalmoscopy on the basis of the characteristic clinical appearance of white, necrotizing retinitis [29] ; AIDS was diagnosed according to Centers for Disease Control and Prevention definitions [30] [31] [32] [33] . Data for all patients diagnosed with CMV retinitis at our center through 31 March 2000 were evaluated for the present study.
Data collection. Sex, race, age, risk factor(s) for HIV infection, and CD4 + cell count were recorded at the time of diagnosis of CMV retinitis. Although the CD4 + cell count often was missing for patients diagnosed with CMV retinitis early during the AIDS epidemic, sufficient information was available to determine whether immune recovery occurred during follow-up in the HAART era. The initial CMV retinitis lesion size in the worse eye was categorized as р24% or у25% of the total retinal area [27] [28] [29] .
After the diagnosis of CMV retinitis, patients had follow-up visits approximately monthly. Patients received antiretroviral therapy, prophylaxis for opportunistic infections, and treatment for CMV retinitis, according to best medical judgment. The use of HAART and anti-CMV therapy and the occurrence of immune recovery in response to HAART were noted prospectively. Immune recovery was defined as an increase in the absolute CD4 + cell count from that at the time of CMV retinitis diagnosis of at least 50 cells/mL, to a level у100 cells/mL [27, 28, 34] , which usually would be sufficient to control CMV disease without anti-CMV therapy [35] . Because HIV load measurement was uncommon before the mid-1990s, data regarding the virological response to HAART were insufficient for use in our study. However, the immunological response to HAART is more strongly associated with improved survival than is the virological response [36] .
Between June 1999 and April 2000, a retrospective chart review recorded the exact antiretroviral, anti-CMV, Pneumocystis carinii pneumonia (PCP) prophylaxis, and Mycobacterium avium complex (MAC) prophylaxis regimens in use at every patient visit (∼10,000 visits) through 31 March 2000. Since 1983, clinic standards have required the prospective generation of a medication flow sheet and detailed, typewritten notes at every visit, which ensures a high degree of completeness of the retrospective information. Unilateral versus bilateral retinitis also was noted for each visit.
Treatment. HAART first became available to the cohort in 1995. Prophylaxis against PCP has been often in use since 1990, and prophylaxis against MAC has been in use since 1996. Because the effect of HAART on the clinical course of HIV/ AIDS has been much greater than that of earlier antiretroviral regimens, antiretroviral therapy was dichotomized according to whether or not HAART had been used. We defined HAART as treatment with у3 antiretroviral agents, including у1 protease inhibitor and/or у1 nonnucleoside reverse-transcriptase inhibitor. Systemic anti-CMV therapy included intravenous ganciclovir, foscarnet, or cidofovir and/or oral ganciclovir but not local therapies (a ganciclovir implant or intravitreal injections) given without a systemic anti-CMV agent. Valganciclovir and other highly potent antiretroviral agents were not in use during the study period. Primary or secondary PCP prophylaxis was defined as the use of у1 systemic agent active against Pneumocystis agent and/or monthly inhaled pentamidine. Similarly, primary or secondary MAC prophylaxis was defined as use of у1 systemic anti-MAC agent.
Mortality. The vital status of patients was followed longitudinally through patient visits and telephone or written communications. For patients whose vital status was unknown, a search of the Social Security Death Index was undertaken in March 2001, and vital status was updated through 31 March 2000.
Statistical methods. The statistical analyses evaluated the relationship of survival to demographic and clinical characteristics, the use of and immunological response to HAART, and the use of systemic anti-CMV treatment and PCP and MAC prophylaxis. Clinical characteristics were coded as fixed covariates, except for a time-updated binary variable that indicated whether CMV retinitis was unilateral or bilateral. Because the benefits of HAART persist for an unknown (probably variable) amount of time after the discontinuation of therapy, the use of HAART and the occurrence of immune recovery were coded conservatively, on the basis of whether either occurred at any time during follow-up, rather than using a time-updated approach. However, because any mortality benefits of PCP prophylaxis, MAC prophylaxis, and systemic anti-CMV treatment were expected to rapidly disappear if therapy was interrupted, these therapies were analyzed as time-updated variables. Because patients who discontinued primary and secondary prophylaxis for opportunistic infections after immune recovery differed from patients who did not receive such therapy while they were still immunodeficient, patients with immune recovery who discontinued systemic anti-CMV, PCP, or MAC medications were considered to be a third category for each of these 3 variables, an approach that allowed them to be censored from analyses of the potential benefits of such medication without removing their other data from the Cox regression models. Values of time-updated variables were assumed to stay constant from one clinic visit until the next visit, death, or censoring, whichever occurred first.
Distributions of demographic and clinical characteristics and of treatments in use at the time of diagnosis with CMV retinitis (by HAART/immunological response status), were compared using x 2 tests. Overall mortality comparisons were made using Kaplan-Meier curves and the log rank test [37] . Percentage reductions and the adjusted percentage reductions in mortality (adjusted for other covariates) were calculated from hazard ratios obtained from Cox regression models [38] , using robust variance estimation [39] . All statistical analyses were conducted using Stata statistical software (version 7.0; Stata). Survival analyses were repeated using only data since 1995, inclusive (corresponding to the HAART era), as a sensitivity analysis.
RESULTS
Patients.
The cohort included 648 consecutive patients with AIDS who had been diagnosed with CMV retinitis between 1 October 1983 and 31 March 2000. Thirty-five (5.4%) had no follow-up visits after the diagnosis of CMV retinitis; medical records were missing for an additional 24 patients (3.7%). The remaining 589 patients (90.9%) provided the data reported hereafter. These patients did not differ significantly from the patients with missing data in demographic or clinical characteristics or in therapeutic regimens in use at the time of CMV retinitis diagnosis, except that the group with missing medical records was more likely to have missing CD4 + cell count data ( ) and was less likely to be receiving PCP prophylaxis
Demographic characteristics were compared by antiretroviral treatment and immune recovery group (table 1) . At the time of diagnosis with CMV retinitis, no significant differences existed among antiretroviral treatment groups in demographic, clinical, and baseline treatment characteristics, except as follows (each with respect to the other 2 groups): (1) patients observed to have immune recovery (many of whom were receiving HAART at the time of CMV retinitis diagnosis) were significantly more likely to have a CD4 + cell count greater than the median; (2) patients who had never used HAART (many of whom received a diagnosis of CMV retinitis early during the AIDS epidemic) were significantly more likely to have CD4 + cell count data missing and were significantly less likely to be receiving MAC prophylaxis; and (3) patients who used HAART but did not gain immune recovery were significantly more likely to be receiving MAC prophylaxis.
Survival. Of the 589 patients followed longitudinally, 504 (85.6%) were known to have died and 62 (10.5%) were known to be living as of 31 March 2000. Vital status as of 31 March 2000 was unknown for 23 (3.9%) patients. Thus, treatment and prophylaxis data were available and vital status was known at the end of follow-up for 566 (87.3%) of the full cohort of 648 patients.
The median duration of survival from the date of CMV retinitis diagnosis for the entire cohort was 8.9 months (table  2) . Patients who used HAART during follow-up had an 81% lower risk of mortality (95% CI, 74%-86%) than patients who did not, surviving for a median of 35.2 versus 7.8 months, a 27-month median prolongation of survival. The median duration of survival was similar in the sensitivity analysis when only data from the HAART era were used: 34.8 months for the group that did receive HAART and 8.0 months for the group that did not.
With subdivision of the group using HAART by whether immune recovery was observed during follow-up, the median survival rate of the group who had immune recovery was not reached; an estimated 81% of them received HAART and were living 48 months after the diagnosis of CMV retinitis (figure 1). This group-followed up for a median of 2.9 years-had a 96% (95% CI, 92%-98%) reduction in mortality compared with the group that did not receive HAART and a 93% (95% CI, 83%-96%) reduction in mortality compared with the group that received HAART but had no immune recovery. The group that received HAART but had no immune recovery survived for a median of 14.5 months, which is a 49% reduction in mortality risk (95% CI, 30%-63%), compared with the group that did not receive HAART. These results were stable after adjusting for the other demographic, clinical, and treatment factors considered. Results of the sensitivity analysis using only data from the HAART era were similar, with an 81% reduction (95% CI, 72%-88%) in mortality for patients who received HAART, a 98% reduction (95% CI, 94%-99%) for those who had immune recovery, and a 52% reduction (95% CI, 29%-67%) for those who did not have immune recovery.
The current use of systemic anti-CMV treatment was associated with a 45% (95% CI, 30%-56%) reduction in mortality risk in the time-updated analysis (figure 2). This effect was reduced to a 28% reduction (95% CI, 8%-43%) after adjusting for confounding by use of HAART and other variables (see table 2), which is still a significant and substantial effect. In the sensitivity analysis using data only from the HAART era, the benefit was more pronounced: anti-CMV therapy was associated with a 69% reduction in CMV retinitis (95% CI, 56%-78%) and with a 43% adjusted reduction (95% CI, 15%-62%) in mortality during the HAART era.
As anticipated, the current use of PCP prophylaxis was associated with reduced mortality: there was a 51% (95% CI, 40%-60%) reduction in mortality risk and a 31% adjusted reduction (95% CI, 17%-43%) after accounting for other variables. This effect also was more pronounced in the sensitivity analysis using only data from the HAART era (43% adjusted reduction; 95% CI, 21%-60%). In contrast, although the current use of MAC prophylaxis was associated with a reduced mortality risk (41% reduction; 95% CI, 29%-52%), adjustment for confounding eliminated the association (adjusted change in risk, 5% increase; 95% CI, 14% reduction to 27% increase). Results regarding MAC prophylaxis were similar in the sensitivity analysis that used only data from the HAART era.
Most demographic and clinical characteristics were not associated with differences in mortality risk, except that patients whose CD4
+ cell count was greater than the median value of 11 cells/mL at the time of CMV retinitis diagnosis had a lower risk of mortality (32% reduction; 95% CI, 15%-45%) than those whose CD4 + cell counts were equal to or less than the median. Patients who were at the median age (37 years) or younger at the time of diagnosis with CMV retinitis, patients with unilateral retinitis, and men with a history of having sex with men each tended to have lower mortality rate than their comparison groups.
DISCUSSION
CMV retinitis continues to occur during the HAART era, with an incidence ∼25% of that during the pre-HAART era [20, 21] . Because the number of persons with AIDS in the United States continues to increase approximately linearly over time [40] , the projected number of new cases of CMV retinitis will increase each year. With the increasing survival time after a diagnosis of CMV retinitis, the number of persons with CMV retinitis under management also is rising substantially at most centers. Our study observed 2 results that are of critical importance for the management of this growing group of patients.
First, we observed a substantial reduction in mortality risk that was associated with the current use of systemic anti-CMV therapy, even after accounting for the effects of HAART. This result agrees with results of early observational studies [8, 41] but disagrees with 2 pre-HAART era studies that had contemporaneous controls and did not observe a significant survival benefit associated with systemic anti-CMV therapy [42, 43] . Two HAART-era observational studies have been reported-1 that observed a survival benefit and 1 that did not [23, 26] . However, because studies that have reported no association between the use of systemic anti-CMV therapy and survival [23, 42, 43] did not evaluate the use of systemic anti-CMV therapy as a time-updated variable, whether patients in fact were receiving anti-CMV therapy during the period just before death is unknown. In contrast, studies that used time-updated analyses-our study and that of Binquet et al. [26] -observed a substantially reduced mortality rate associated with the use of systemic anti-CMV therapy. In the only pertinent clinical trial with a median follow-up time exceeding several months [43] , the magnitude of reduction in mortality between groups assigned to receive systemic anti-CMV therapy, compared with those who received no systemic anti-CMV therapy, was similar to that observed in our study, although the difference observed in that trial was not statistically significant with the power available. The results of several virological studies have predicted that anti-CMV therapy should reduce mortality in patients with CMV disease. During the pre-HAART era, patients with AIDS who had cytomegaloviremia that was detectable by PCR assays had a higher risk of CMV disease and of mortality [44] [45] [46] [47] . Among patients with cytomegaloviremia, a higher CMV DNA load was associated with higher mortality [10, 44, [46] [47] [48] . Similarly, detectable CMV antigenemia was associated with an increased mortality risk during the pre-HAART era [49, 50] .
Taken in aggregate, these clinical and virological results suggest that systemic anti-CMV therapy reduces mortality substantially among patients with CMV retinitis and severe HIV-induced immunodeficiency. Several potential mechanisms exist by which such a benefit could occur. Autopsy evaluations of patients with CMV retinitis have indicated that most patients had extraocular CMV infection that was often undetected [51] ; the control of visceral CMV disease by systemic anti-CMV therapy [52, 53] may improve survival. Also, anti-CMV therapy is associated with a clearance of CMV viremia [44, 45, 47] , which could interrupt the reported direct adverse immunological effects of CMV [53] . Finally, the clearing of cytomegaloviremia with systemic anti-CMV therapy may interrupt the transactivation of HIV by CMV [54, 55] . In a clinical trial that compared initial treatment with foscarnet with intravenous ganciclovir for CMV retinitis, both regimens were associated with reduced levels of the HIV p24 antigen, even though ganciclovir is not known to have a direct antiretroviral effect [56] , which suggests that the suppression of CMV impaired HIV replication.
Second, the mortality risk for patients who did not develop immune recovery in response to HAART was substantially reduced, to a level about one-half that of those who did not receive HAART. Overall, patients who used HAART had an 81% reduction in mortality with respect to those who did not receive HAART, a result that is similar to that reported in previous studies [22] [23] [24] [25] [26] . The profound reduction in the mortality rate of patients who had immune recovery in response to HAART was expected, but the substantial reduction in the mortality rate of the group who continued to have profound immunodeficiency despite receiving HAART was a striking new finding that has not been previously reported. This group survived a median of 14.5 months, well above the range of 4 to ∼12 months reported during the pre-HAART era [5-11, 22, 41, 57, 58] and well above the median survival rate of 7.8 months reported in the group that did not receive HAART.
Had we had excluded patients who received HAART only briefly during follow-up or had we used a time-updated HAART analysis, the observed differences in mortality may have been even larger. Results were confirmed by sensitivity analysis using only data from the HAART era.
Potential explanations for reduced mortality among patients who continued to have profound immunodeficiency while using HAART include the following: (1) some patients may have had immune recovery to a degree less than that included by our definition but sufficient to improve survival; (2) some patients may have benefited from control of the HIV replication by HAART [35] , even though immune recovery did not occur; and (3) antiretroviral therapy could have benefits beyond those measured by its effects on CD4 + cell counts and HIV load measurements [59] , possibly by reducing HIV fitness [60] .
Other observations from our study included the confirmation that PCP prophylaxis provides a substantial survival benefit over and above the benefit of HAART for patients with CMV retinitis and AIDS who continue to have severe immunodeficiency. On the other hand, patients with HAART-induced immune recovery who discontinued anti-PCP prophylaxis had a very low mortality risk (data not shown), which suggests that the discontinuation of PCP prophylaxis in the setting of immune recovery, as per current recommendations [61, 62] , does not adversely affect survival.
In contrast, we did not observe an independent survival benefit of MAC prophylaxis among our patients. Other studies of the relationship between MAC prophylaxis and survival among patients with advanced AIDS have shown mixed results-some have reported improved survival [3, 63] , and others have found no association [64] [65] [66] [67] . Thus, although MAC prophylaxis is indicated for patients with AIDS and a CD4 + cell count of !50 cells/mL [36] , to reduce the risk of MAC disease, it is unclear whether MAC prophylaxis reduces mortality among such patients.
As for all clinical studies, our results must be evaluated with a consideration of methodological limitations and potential biases. Nonrandomized studies of treatments lack a mechanism to prevent selection bias. In the present case, the treatments considered were all clinically indicated and could not ethically have been withheld in order to conduct a randomized trial. However, the magnitude of the benefit observed makes it unlikely that the effects of anti-CMV therapy and HAART were due to selection bias. The concordance of our results with those of other reports and with biological plausibility also supports our conclusions. It could be argued that the discontinuation of medication shortly before death (e.g., to enter a hospice) could explain the apparent survival benefit of systemic anti-CMV treatment and PCP prophylaxis. However, if this were the case, it would be difficult to explain the lack of observed benefit of MAC prophylaxis in our cohort. In our cohort, the cessation of anti-CMV treatment to enter a hospice was rare because of concerns about the affect of vision loss on quality of life. Although the lack of virus load data in our study is a limitation, such information would have been useful primarily to evaluate the mechanism of benefit in patients receiving HAART who did not have immune recovery, and this information would not have altered the fundamental conclusions of the study regarding the use of treatment. The rate of completed follow-up for mortality was relatively high in our study, although it remains possible that subjects lost to follow-up may have differed from those observed. Although our center is a referral center for ocular complications of AIDS, an estimated у80% of CMV retinitis cases in the Baltimore metropolitan area are managed at our center, having been referred from both private and academic sources [27, 28] , which increases the generalizability of our results. The demographic makeup of our cohort, with a relatively high proportion of women, blacks, and injection drug users, mirrors the epidemiology of AIDS in our region and reflects the likely future epidemiology of AIDS in the United States. Our results were qualitatively similar in sensitivity analyses that restricted observations to those during the HAART era, which suggests that unrecognized cohort effects are unlikely to have affected our conclusions to a substantial degree and confirms that the observed benefit of systemic anti-CMV therapy (and of PCP prophylaxis) is relevant during the era of HAART.
Patients with AIDS and CMV retinitis have a high mortality risk, but HAART substantially reduces this risk, even when HAART does not reverse profound immunodeficiency. Systemic anti-CMV therapy also reduces the mortality risk in these patients by ∼30% over and above the benefit of HAART. Our observations suggest that the combined direct effects of continued HAART and anti-CMV therapy would reduce by 65% the mortality risk of patients for whom HAART does not induce immunological recovery. The use of HAART is indicated for all patients with AIDS and CMV retinitis, and the use of systemic anti-CMV therapy is indicated as long as severe immunodeficiency persists, even when retinitis management uses local therapy.
